Indian fund managers directed fresh investments into pharmaceutical and non-banking financial companies during April. The moves targeted defensive stocks amid concerns over oil prices and tensions in West Asia.
Pharmaceutical firms drew particular attention because of opportunities such as the semaglutide patent expiry. Stocks including Aurobindo Pharma, Sun Pharma, Torrent Pharma and Mankind Pharma featured in the buying activity by equity schemes.